Cargando…

Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Detalles Bibliográficos
Autores principales:	Kaufman-Janette, Joely, Avelar, Rui L, Biesman, Brian S, Draelos, Zoe Diana, Gross, John E, Jones, Derek H, Lupo, Mary P, Maas, Corey S, Schlessinger, Joel, Shamban, Ava Teresa, Sundaram, Hema, Weinkle, Susan H, Young, Vernon L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Corrigenda
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598191/ https://www.ncbi.nlm.nih.gov/pubmed/34309676 http://dx.doi.org/10.1093/asj/sjab229

Ejemplares similares

The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021)

Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Lorenc, Z Paul, et al.
Publicado: (2021)

Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies
por: Beer, Kenneth R., et al.
Publicado: (2019)

The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Lorenc, Z Paul, et al.
Publicado: (2021)

PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data
por: Ogilvie, Patricia, et al.
Publicado: (2022)

PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data
por: Taylor, Susan C., et al.
Publicado: (2021)

PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
por: Solish, Nowell, et al.
Publicado: (2022)

Efficacy and Safety of a New Resilient Hyaluronic Acid Filler in the Correction of Moderate-to-Severe Dynamic Perioral Rhytides: A 52-Week Prospective, Multicenter, Controlled, Randomized, Evaluator-Blinded Study
por: Sundaram, Hema, et al.
Publicado: (2022)

A Preclinical Study Comparing the Activity and Potency of OnabotulinumtoxinA and PrabotulinumtoxinA
por: Rupp, David C, et al.
Publicado: (2023)

A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines
por: Schlessinger, Joel, et al.
Publicado: (2021)

Safety and Efficacy of PrabotulinumtoxinA (Nabota(®)) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study
por: Kim, Da-ye, et al.
Publicado: (2018)

Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?
por: Kaufman-Janette, Joely, et al.
Publicado: (2021)

Efficacy, Safety, and Subject Satisfaction of PrabotulinumtoxinA for Moderate-to-Severe Crow’s Feet: A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
por: Lee, Soo-Kyung, et al.
Publicado: (2023)

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines
por: Dayan, Steven, et al.
Publicado: (2022)

Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines
por: Solish, Nowell, et al.
Publicado: (2022)

Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate‐to‐severe nasolabial folds: A 64‐week, prospective, multicenter, controlled, randomized, double‐blind and within‐subject study
por: Kaufman‐Janette, Joely, et al.
Publicado: (2019)

Safe and Effective Chin Augmentation With the Hyaluronic Acid Injectable Filler, VYC-20L
por: Beer, Kenneth, et al.
Publicado: (2021)

Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials
por: Solish, Nowell, et al.
Publicado: (2022)

Injection Guidelines for Treating Midface Volume Deficiency With Hyaluronic Acid Fillers: The ATP Approach (Anatomy, Techniques, Products)
por: Trévidic, Patrick, et al.
Publicado: (2022)

Angiomyolipoma of the Glabellar Region
por: Kim, Hyo Joong, et al.
Publicado: (2017)

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study
por: Green, Jeremy B., et al.
Publicado: (2021)

Corrigendum to: Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?
por: Turkheimer, Federico E, et al.
Publicado: (2020)

Correction: Preventive Behaviors Conveyed on YouTube to Mitigate Transmission of COVID-19: Cross-Sectional Study
por: Basch, Corey H, et al.
Publicado: (2020)

Glabellar Presentation, Its Incidence and Termination
por: Mudaliar, A. L.
Publicado: (1934)

Glabellar flap technique in oculoplastic surgery
por: Balchev, Georgi, et al.
Publicado: (2022)

Glabellar and auricular leukemia cutis in CLL
por: Steinman, Bradley, et al.
Publicado: (2022)

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)
por: Carruthers, Jean D., et al.
Publicado: (2020)

A Randomized, Controlled, Evaluator-Blinded, Multi-Center Study of Hyaluronic Acid Filler Effectiveness and Safety in Lip Fullness Augmentation
por: Weiss, Robert, et al.
Publicado: (2021)

New Uses of AbobotulinumtoxinA in Aesthetics
por: Schlessinger, Joel, et al.
Publicado: (2017)

Commentary: A technical revisit to the glabellar flap
por: Singh, Manpreet, et al.
Publicado: (2022)

Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
por: Humphrey, Shannon, et al.
Publicado: (2023)

Optimizing Outcomes When Treating Glabellar Lines
por: Solish, Nowell, et al.
Publicado: (2023)

Corrigendum: Annexin A2 promotes phagophore assembly by enhancing Atg16(+) vesicle biogenesis and homotypic fusion
por: Morozova, Kateryna, et al.
Publicado: (2015)

Noninvasive Submental Fat Compartment Treatment
por: Shamban, Ava T.
Publicado: (2016)

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
por: Cardoso, F, et al.
Publicado: (2017)

Corrigendum: Directionality of substrate translocation of the hemolysin A Type I secretion system
por: Lenders, Michael H. H., et al.
Publicado: (2018)

Corrigendum: Tuning the optical response of a dimer nanoantenna using plasmonic nanoring loads
por: Panaretos, Anastasios H., et al.
Publicado: (2016)

Corrigendum: Universality in boundary domain growth by sudden bridging
por: Saberi, A. A., et al.
Publicado: (2016)

Corrigendum: A universal mechanism of extreme events and critical phenomena
por: Wu, J. H., et al.
Publicado: (2016)

Corrigendum: Efficient design, accurate fabrication and effective characterization of plasmonic quasicrystalline arrays of nano-spherical particles
por: Namin, Farhad A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_90ap4fb483ugs3q1ms1v2guhr0